familial heterozygous hypercholesterolaemia
Cardiovascular · 2023–2023
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alirocumab Treatment of familial heterozygous hypercholesterolaemia (he-FH) and non-familial hypercholesterolaemia (non-FH), and prevention of cardiovascular events. | Mar 2023 | Recommended | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.